Neuropsychiatric Research Center of Orange County

Orange, California 92868

0 studies enrolling now · 17 studies all time

What they study most

ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Dysfunction, Depression, Major Depressive Disorder, Negative Symptoms, Opioid Use Disorder, Opioid-related Disorders, PTSD, Rheumatoid Arthritis, Schizoaffective Disorder

Studies at this site

• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia — Completed
• Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions — Completed
• Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions — Completed
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment — Stopped early
• Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) — Completed
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD — Completed
• ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate — Completed
• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD — Completed
• Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder — Completed
• Pediatric Schizophrenia Efficacy and Safety Study — Completed
• A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD — Completed
• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia — Stopped early
• Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia — Completed
• Bioavailability of LY03004 and Risperdal® Consta® — Completed
• Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder — Completed